• Other
  • Exited

Vascular Pharmaceuticals Inc. is developing a first in class, humanized monoclonal antibody (mAb) that binds to a unique target; the C-loop domain sequence within the αVβ3 receptor, a selectively expressed component of the insulin-like growth factor-I (IGF-I) signaling pathway. This pathway is stimulated in the presence of hyperglycemia and contributes to nephropathy and accelerated atherosclerosis development in diabetic animal models. VPI-2690B has demonstrated slowing of nephropathy and atherosclerosis progression in animals without evidence of detrimental off target effects..